EUVIMEDEUVIMED entdecken
Crossref

Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase

Bing-Jie Liang, Le-Xuan Dong, Yang Yu, Jing Zhang, Dan-Dan Wang, Wen-Yao He, Shu-Xia Wang, Li-Wei Zou iD

Chemistry & Biodiversity · 2025

DOI: 10.1002/cbdv.202500381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Bing-Jie Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Agents, Drug Discovery, Enzyme Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is closely related to the occurrence and development of many diseases, such as diabetes, hypertension, and hyperlipidemia. As an important digestive enzyme, human pancreatic lipase (hPL) is involved in the metabolism and absorption of dietary fat and is a key target of overweight and obesity. Therefore, the inhibition of hPL enzyme is a feasible strategy for the prevention and treatment of obesity. In this study, we collected a series of marketed hypoglycemic and cardiovascular drugs and evaluated their inhibitory activity against hPL. Among them, ticagrelor (HC‐14), prasugrel (HC‐18), amlodipine (HC‐26), simvastatin (HC‐32), and lovastatin (HC‐33) had strong inhibitory activity against hPL. In order to further clarify the inhibition mechanism, inhibition kinetics and molecular docking were carried out, and results revealed that HC‐14 was a mixed inhibitory manner on hPL activity. HC‐14 also showed similar inhibitory effect on human carboxylesterase 2 (hCES2), but poor inhibitory effect on other five serine hydrolases. Further studies showed that HC‐14 significantly inhibited hPL activity in AR42J cells, resulting in dose‐dependent inhibition. Overall, the above results suggest that ticagrelor is a cardiovascular drug that inhibits hPL, which also provides an important reference for the search and development of other drugs for the treatment of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular AgentsDrug DiscoveryEnzyme InhibitorsHypoglycemic AgentsLipaseHumansDose-Response Relationship, DrugMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipTicagrelor

Stichwörter der Autor:innen

cardiovascular drugshuman pancreatic lipasehypoglycemic drugsinhibitor screeningobesity

Substanzen

Cardiovascular AgentsEnzyme InhibitorsHypoglycemic AgentsLipasePNLIP protein, humanTicagrelor

Autor:innen und Institutionen

  • Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • College of Pharmacy, Dalian Medical University, Dalian, Liaoning Province, China.
  • Collaborative Innovation Center of Tumor Marker Detection Technology, Equipment and Diagnosis Therapy Integration in Universities of Shandong, Shandong Province Key Laboratory of Detection Technology for Tumor Makers, S…
  • SPH Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd., Shanghai, China.

ORCID-Profile: Li-Wei Zou

Zitieren

APA

Liang, B. J., Dong, L. X., Yu, Y., Zhang, J., Wang, D. D., He, W. Y., Wang, S. X., & Zou, L. W. (2025). Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202500381

Vancouver

Liang BJ, Dong LX, Yu Y, Zhang J, Wang DD, He WY, et al. Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202500381

BibTeX
@article{Liang2025,
  author = {Liang, Bing-Jie and Dong, Le-Xuan and Yu, Yang and Zhang, Jing and Wang, Dan-Dan and He, Wen-Yao and Wang, Shu-Xia and Zou, Li-Wei},
  title = {Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  doi = {10.1002/cbdv.202500381}
}
Kostenlos starten →